MAAT INDEX

CLAIM #56421 · Thermo Fisher Scientific Inc (TMO) · 2024Q2 earnings call · Jul 24, 2024 · due Dec 31, 2024

For the year we're assuming between $1.3 billion and $1.5 billion in net capital expenditures and free cash flow in the range of $6.5 billion to $7 billion.

Stephen Williamson · CFO

PENDING
graded after results covering Dec 31, 2024 are reported

How to check this claim

Look at: Full-year net capital expenditures and full-year free cash flow, as reported by the company

It came true if: Net capital expenditures between $1.3 billion and $1.5 billion, AND free cash flow between $6.5 billion and $7.0 billion

Where: Company FY2024 earnings release / 10-K cash flow statement and management commentary (Q4 2024 earnings call)

Verify independently

SEC filings for TMO · Claim quote is verbatim from the 2024Q2 earnings call.